Medscape

Staying the Course After EGFR Progression: A Practical Guide to Treatment in NSCLC

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...
PharmiWeb

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Study finds CDK4/6 plus EGFR blockade kills pancreatic cancer cells without KRAS drugs

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
News Medical

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Labiotech.eu

How colorectal cancer treatment is evolving in 2026

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
CURE

How Recent Lung Cancer FDA Approvals are Shaping Treatment for Patients

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
Healio

Wait-time policy tied to increased kidney transplant rates for Black candidates

Implementation of a race-neutral eGFR equation contributed to more than 20,000 wait-time modifications and more kidney transplants for Black transplant candidates, according to study data published in ...

BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
Healio

Finerenone safely lowers albuminuria among adults with nephrectomy history

Finerenone demonstrated safety and reduced albuminuria for patients with chronic kidney disease, type 2 diabetes and a ...

Leclaza Combination Therapy Proves Effective for 'Brain Metastatic Lung Cancer'... Accelerating the Chase for No. 1 Lung Cancer Treatment

The primary battleground in the competition for lung cancer treatments is shifting toward "brain metastasis." This shift comes as new research has ...
Scientific Research Publishing

A Multimodal Machine-Learning Framework for Predicting Lithium-Associated Renal Dysfunction from Synthetic Biomarker Trajectories ()

Long-term lithium therapy remains the most effective maintenance treatment for bipolar disorder, yet it poses a significant risk of progressive renal impairment in a subset of patients. Early ...